Clinical Trials Logo

Arthritis clinical trials

View clinical trials related to Arthritis.

Filter by:

NCT ID: NCT01649999 Completed - Clinical trials for Arthritis, Rheumatoid

A Study to Evaluate the Efficacy and Safety of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects

Start date: March 1, 2012
Phase: Phase 2
Study type: Interventional

This study is to evaluate the efficacy and safety of ASP015K monotherapy and to evaluate the dose-dependent response of ASP015K in moderate to severe Rheumatoid Arthritis (RA) subjects given ASP015K for 12 weeks.

NCT ID: NCT01649817 Completed - Clinical trials for Rheumatoid Arthritis

A Retrospective Observational Study on Compliance in Patients With Rheumatoid Arthritis on Treatment With RoActemra/Actemra (Tocilizumab) in Clinical Practice (REMISSION II)

Start date: May 2012
Phase: N/A
Study type: Observational

This multicenter, retrospective observational study will evaluate compliance an reasons for withdrawal in patients with moderate to severe active rheumatoid arthritis on treatment with intravenous RoActemra/Actemra (tocilizumab) in daily clinical practice. Data will be collected from each eligible patient over a period of 6 months.

NCT ID: NCT01649804 Completed - Clinical trials for Rheumatoid Arthritis

A Long-Term Safety Extension Study of WA19926 in Patients With Rheumatoid Arthritis

Start date: July 2012
Phase: Phase 3
Study type: Interventional

This extension study of WA19926 will assess the long-term safety and the efficacy of RoActemra/Actemra (tocilizumab) treatment in patients with rheumatoid arthritis. Patients who have completed the core study WA19926 are eligible to participate. Patients will receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks. The anticipated time on study drug is 104 weeks.

NCT ID: NCT01647451 Completed - Clinical trials for Rheumatoid Arthritis

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis

Start date: September 2012
Phase: Phase 2
Study type: Interventional

This trial is conducted in Europe. The aim of the trial is to evaluate the change in disease activity following intravenous (i.v.) administration of two doses of NNC0114-0006 compared to placebo in subjects with active rheumatoid arthritis (RA) on background methotrexate (MTX) therapy.

NCT ID: NCT01645280 Completed - Clinical trials for Arthritis, Rheumatoid

A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy

Start date: August 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of ustekinumab and CNTO 1959 in reducing the signs and symptoms of disease in patients with active rheumatoid arthritis (RA) despite concomitant methotrexate (MTX) therapy and to evaluate the safety of ustekinumab and CNTO 1959 in this population.

NCT ID: NCT01643928 Completed - Clinical trials for Rheumatoid Arthritis

Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)

Start date: August 16, 2012
Phase: N/A
Study type: Interventional

This extension study will evaluate the safety (including immunogenicity) of treatment with rituximab-Pfizer, as well as the safety and immunogenicity after transitioning from rituximab-US or rituximab-EU to rituximab-Pfizer. This study will provide continued treatment access to subjects with active rheumatoid arthritis who have participated for at least 16 weeks in other studies in the rituximab Pfizer program.

NCT ID: NCT01641952 Completed - Clinical trials for Rheumatoid Arthritis

An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-TNF Agent

Start date: October 2011
Phase: N/A
Study type: Observational

This observational, prospective, multicenter study will evaluate the efficacy and safety of MabThera/Rituxan in patients with active rheumatoid arthritis and an inadequate response or intolerance to one anti-TNF therapy. Patients who receive MabThera/Rituxan according to the current standard and in line with the summary of product characteristics at a dose of 1000 mg intravenously on Days 1 and 15 will be followed for 20 weeks.

NCT ID: NCT01641471 Completed - Pain Clinical Trials

Evaluation of Electrical Nerve Stimulation (TENS) Therapy for Pain Relief Following Total Knee Arthroplasty (TKA)

Start date: December 2012
Phase: N/A
Study type: Interventional

Evaluation of Electrical Nerve Stimulation (TENS) Therapy for Pain Relieft Following Total Knee Arrhtoplasty (TKA)

NCT ID: NCT01640548 Completed - Clinical trials for Rheumatoid Arthritis

A Retrospective Chart Review on the Use of Biologics in Monotherapy for the Treatment of Patients With Rheumatoid Arthritis

Start date: September 2012
Phase: N/A
Study type: Observational

This non-interventional, retrospective, cross sectional chart review study will evaluate the management of rheumatoid arthritis patients with a biologic in monotherapy. Data from eligible patients will be collected from the patient's last visit on the prior rheumatoid arthritis treatment and from the most recent visit for the biological monotherapy.

NCT ID: NCT01638715 Completed - Clinical trials for Rheumatoid Arthritis

A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action

Start date: May 2012
Phase: Phase 4
Study type: Interventional

The purpose of this study is to find biological response patterns of patients with rheumatoid arthritis to drugs with different biologic modes of action. This study should help to predict therapeutic responses and to find the right therapy for the right patient.